Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
611168-24-2
Molecular formula
C33H38O6
Molecular weight
530.6 g/mol
Drug class
Nitrogen-scavenging prodrugglycerol ester of phenylbutyrate
Mechanism of action
Hydrolysed to phenylbutyrate, which is oxidised to phenylacetate. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is excreted in urine and provides an alternative pathway for nitrogen waste elimination in urea-cycle disorders.
Indications / reported uses
Chronic management of patients with urea-cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino-acid supplementation alone; not for treatment of acute hyperammonaemia
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Glycerol Phenylbutyrate Environmental Risk Assessment (ERA) (the Glycerol Phenylbutyrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.